

Ngaihang Victor Chong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6077305/publications.pdf>

Version: 2024-02-01

125
papers

8,198
citations

116194

36
h-index

58552

86
g-index

129
all docs

129
docs citations

129
times ranked

6659
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine Learning OCT Predictors of Progression from Intermediate Age-Related Macular Degeneration to Geographic Atrophy and Vision Loss. <i>Ophthalmology Science</i> , 2022, 2, 100160.	1.0	6
2	Correlation of Optical Coherence Tomography Angiography Characteristics with Visual Function to Define Vision-Threatening Diabetic Macular Ischemia. <i>Diagnostics</i> , 2022, 12, 1050.	1.3	3
3	Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. <i>Eye</i> , 2022, , .	1.1	1
4	Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy. <i>Ophthalmology</i> , 2021, 128, 561-573.	2.5	15
5	Diabetic Macular Ischemia: Influence of Optical Coherence Tomography Angiography Parameters on Changes in Functional Outcomes Over One Year. , 2021, 62, 9.		23
6	Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia. <i>Ophthalmologica</i> , 2021, 244, 451-464.	1.0	12
7	Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 30.	0.9	9
8	Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. <i>Health Technology Assessment</i> , 2021, 25, 1-104.	1.3	1
9	Endpoints: The beginning of a new treatment?. <i>Ophthalmologica</i> , 2021, 244, 365-367.	1.0	1
10	Reply. <i>Ophthalmology</i> , 2021, 128, e46-e47.	2.5	0
11	Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. <i>Eye</i> , 2020, 34, 1592-1599.	1.1	22
12	Incorporating Optical Coherence Tomography Macula Scans Enhances Cost-effectiveness of Fundus Photography-Based Screening for Diabetic Macular Edema. <i>Diabetes Care</i> , 2020, 43, 2959-2966.	4.3	7
13	Radiotherapy for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2020, 8, CD004004.	1.5	2
14	Aflibercept Reduces Retinal Hemorrhages and Intravitreal Microvascular Abnormalities But Not Venous Beading. <i>Ophthalmology Retina</i> , 2020, 4, 689-694.	1.2	11
15	Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vessels in Diabetic retinopathy (EMERALD). <i>BMJ Open</i> , 2019, 9, e027795.	0.8	7
16	A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy. <i>Lasers in Medical Science</i> , 2019, 34, 1345-1351.	1.0	19
17	Diabetic macular oedema and diode subthreshold micropulse laser (DIAMONDS): study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 122.	0.7	22
18	Randomised trial of wide-field guided PRP for diabetic macular oedema treated with ranibizumab. <i>Eye</i> , 2019, 33, 930-937.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Microperimetry in Age-Related Macular Degeneration: An Evidence-Base for Pattern Deviation Probability Analysis in Microperimetry. <i>Translational Vision Science and Technology</i> , 2019, 8, 48.	1.1	6
20	COMPARING MICROPERIMETRIC AND STRUCTURAL FINDINGS IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION AND DIABETIC MACULAR EDEMA. <i>Retina</i> , 2019, 39, 446-451.	1.0	5
21	Diabetic macular oedema: under-represented in the genetic analysis of diabetic retinopathy. <i>Acta Ophthalmologica</i> , 2018, 96, 1-51.	0.6	7
22	The use of microperimetry in assessing visual function in age-related macular degeneration. <i>Survey of Ophthalmology</i> , 2018, 63, 40-55.	1.7	47
23	Optical Coherence Tomography Angiography in Familial Exudative Vitreoretinopathy: Clinical Features and Phenotype-Genotype Correlation. , 2018, 59, 5726.		21
24	A Retrospective Analysis of the Effect of Subretinal Hyper-Reflective Material and Other Morphological Features of Neovascular Age-Related Macular Degeneration on Visual Acuity Outcomes in Eyes Treated with Intravitreal Aflibercept over One Year. <i>Vision (Switzerland)</i> , 2018, 2, 5.	0.5	13
25	STRUCTURAL-FUNCTIONAL CORRELATION IN PATIENTS WITH DIABETIC MACULAR EDEMA. <i>Retina</i> , 2017, 37, 881-885.	1.0	14
26	Macula Society Collaborative Retrospective Study of Ocriplasmin for Symptomatic Vitreomacular Adhesion. <i>Ophthalmology Retina</i> , 2017, 1, 413-420.	1.2	9
27	Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1217-1224.	1.5	57
28	Comparing Macular Thickness Measurements in Patients with Diabetic Macular Edema with the Optos Spectral OCT/SLO and Heidelberg Spectralis HRA + OCT. <i>Vision (Switzerland)</i> , 2017, 1, 2.	0.5	1
29	Are we making good use of our public resources? The false-positive rate of screening by fundus photography for diabetic macular oedema. <i>Hong Kong Medical Journal</i> , 2017, 23, 356-64.	0.1	22
30	Retinal Biochemistry, Physiology and Cell Biology. <i>Developments in Ophthalmology</i> , 2016, 55, 18-27.	0.1	2
31	Subfoveal choroidal thickness in patients with diabetic retinopathy and diabetic macular oedema. <i>Eye</i> , 2016, 30, 1568-1572.	1.1	42
32	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. <i>Eye</i> , 2016, 30, 270-286.	1.1	106
33	Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy. <i>Clinical Ophthalmology</i> , 2015, 9, 527.	0.9	82
34	Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema. <i>Clinical Ophthalmology</i> , 2015, 9, 2305.	0.9	10
35	Sequential therapy with ranibizumab and dexamethasone intravitreal implant is better than dexamethasone monotherapy for macular oedema due to retinal vein occlusion. <i>British Journal of Ophthalmology</i> , 2015, 99, 210-214.	2.1	13
36	Improvement in Vision-Related Function with Intravitreal Aflibercept. <i>Ophthalmology</i> , 2015, 122, 571-578.	2.5	37

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. <i>British Journal of Ophthalmology</i> , 2015, 99, 92-97.	2.1	45
38	Comparison of Optomap ultrawide-field imaging versus slit-lamp biomicroscopy for assessment of diabetic retinopathy in a real-life clinic. <i>Clinical Ophthalmology</i> , 2014, 8, 1413.	0.9	11
39	Progression of preproliferative to proliferative diabetic retinopathy: a 3-year study in the Oxford population-based diabetic retinopathy screening programme. <i>Diabetic Medicine</i> , 2014, 31, 1018-1019.	1.2	3
40	Age-related macular degeneration: current treatment options. <i>The Prescriber</i> , 2014, 25, 25-28.	0.1	0
41	UNDERSTANDING INDOCYANINE GREEN ANGIOGRAPHY IN POLYPOIDAL CHOROIDAL VASCULOPATHY. <i>Retina</i> , 2014, 34, 2397-2406.	1.0	34
42	Author reply. <i>Ophthalmology</i> , 2014, 121, e5-e6.	2.5	3
43	Improving the cost-effectiveness of photographic screening for diabetic macular oedema: a prospective, multi-centre, UK study. <i>British Journal of Ophthalmology</i> , 2014, 98, 1042-1049.	2.1	48
44	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). <i>British Journal of Ophthalmology</i> , 2014, 98, 1144-1167.	2.1	463
45	Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration. <i>Ophthalmology</i> , 2014, 121, 193-201.	2.5	693
46	Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1185-1192.	1.5	10
47	Factors Affecting Reading Speed in Patients with Diabetic Macular Edema Treated with Laser Photocoagulation. <i>PLoS ONE</i> , 2014, 9, e105696.	1.1	28
48	Medical management for the prevention and treatment of diabetic macular edema. <i>Survey of Ophthalmology</i> , 2013, 58, 459-465.	1.7	43
49	The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. <i>Eye</i> , 2013, 27, 1429-1431.	1.1	34
50	Optimisation of an automated drusen-quantifying software for the analysis of drusen distribution in patients with age-related macular degeneration. <i>Eye</i> , 2013, 27, 554-560.	1.1	4
51	New Therapies for Diabetes Management. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-126-S-135.	2.4	1
52	Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study. <i>Health Technology Assessment</i> , 2013, 17, 1-142.	1.3	49
53	Age-related macular degeneration: the importance of family history as a risk factor. <i>British Journal of Ophthalmology</i> , 2012, 96, 427-431.	2.1	58
54	New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. <i>Eye</i> , 2012, 26, 485-493.	1.1	104

#	ARTICLE	IF	CITATIONS
55	Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema. <i>Eye</i> , 2012, 26, 1078-1085.	1.1	22
56	Visual Improvement following Continuous Positive Airway Pressure Therapy in Diabetic Subjects with Clinically Significant Macular Oedema and Obstructive Sleep Apnoea: Proof of Principle Study. <i>Respiration</i> , 2012, 84, 275-282.	1.2	41
57	HIGH PREVALENCE OF SLEEP DISORDERED BREATHING IN PATIENTS WITH DIABETIC MACULAR EDEMA. <i>Retina</i> , 2012, 32, 1791-1798.	1.0	52
58	Biological, Preclinical and Clinical Characteristics of Inhibitors of Vascular Endothelial Growth Factors. <i>Ophthalmologica</i> , 2012, 227, 2-10.	1.0	40
59	Managing retinal vein occlusion. <i>BMJ: British Medical Journal</i> , 2012, 344, e499-e499.	2.4	25
60	Branch retinal vein occlusion. <i>BMJ, The</i> , 2012, 345, e8373-e8373.	3.0	2
61	Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. <i>Ophthalmology</i> , 2012, 119, 2537-2548.	2.5	1,947
62	Optimization of In Vivo Confocal Autofluorescence Imaging of the Ocular Fundus in Mice and Its Application to Models of Human Retinal Degeneration. , 2012, 53, 1066.		56
63	Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization. <i>Experimental and Molecular Pathology</i> , 2012, 92, 64-73.	0.9	49
64	Identification of anti-retinal antibodies in patients with age-related macular degeneration. <i>Experimental and Molecular Pathology</i> , 2012, 93, 193-199.	0.9	79
65	Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. , 2012, , 161-169.		0
66	Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without Ranibizumab. <i>Eye</i> , 2011, 25, 149-153.	1.1	15
67	The significance of the complement system for the pathogenesis of age-related macular degeneration – current evidence and translation into clinical application. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2011, 249, 163-174.	1.0	76
68	Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab. <i>Eye</i> , 2011, 25, 1612-1616.	1.1	8
69	A Pilot Study on the Combination Treatment of Reduced-Fluence Photodynamic Therapy, Intravitreal Ranibizumab, Intravitreal Dexamethasone and Oral Minocycline for Neovascular Age-Related Macular Degeneration. <i>Ophthalmologica</i> , 2011, 225, 200-206.	1.0	15
70	Radiotherapy for neovascular age-related macular degeneration. <i>The Cochrane Library</i> , 2010, , CD004004.	1.5	38
71	Optical coherence tomography study of adult vitelliform macular detachment in a patient with basal laminar drusen. <i>International Ophthalmology</i> , 2010, 30, 333-335.	0.6	0
72	Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. <i>Eye</i> , 2010, 24, 1018-1023.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Retinal biochemistry, physiology, and cell biology. , 2010, , 15-22.		1
74	Local anesthesia for cataract surgery. Journal of Cataract and Refractive Surgery, 2010, 36, 133-152.	0.7	54
75	Color Contrast and Drusen Area. Ophthalmology, 2010, 117, 1280-1281.	2.5	4
76	Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. British Journal of Ophthalmology, 2009, 93, 1341-1344.	2.1	163
77	Micropulse diode laser photocoagulation for central serous chorioâ€retinopathy. Clinical and Experimental Ophthalmology, 2009, 37, 801-805.	1.3	48
78	Reply to Drs Blann and Lip. Eye, 2009, 23, 495-495.	1.1	0
79	Should avastin be used to treat age-related macular degeneration in the NHS? â€ Yes. Eye, 2009, 23, 1247-1249.	1.1	1
80	Visual function vs quality of life assessment in patients with laser-treated diabetic macular oedema. Acta Ophthalmologica, 2009, 87, 0-0.	0.6	0
81	The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study. BMC Ophthalmology, 2008, 8, 15.	0.6	18
82	Age-related macular degeneration: a perspective on genetic studies. Eye, 2008, 22, 768-776.	1.1	58
83	Looking beyond Lucentis on the management of macular degeneration. Eye, 2008, 22, 742-750.	1.1	7
84	Computerized Model of Cost-Utility Analysis for Treatment of Age-Related Macular Degeneration. Ophthalmology, 2008, 115, 2192-2198.	2.5	34
85	Systemic Complement Activation in Age-Related Macular Degeneration. PLoS ONE, 2008, 3, e2593.	1.1	308
86	Estimation of Systemic Complement C3 Activity in Age-Related Macular Degeneration. JAMA Ophthalmology, 2007, 125, 515.	2.6	82
87	Sudden visual loss. Lancet, The, 2007, 370, 590.	6.3	1
88	Pathological and Electrophysiological Features of a Canine Coneâ€Rod Dystrophy in the Miniature Longhaired Dachshund. , 2007, 48, 4240.		38
89	Perimacular retinal folds and nonaccidental injuryâ€Yes, No, or Maybe?. Eye, 2007, 21, 3-4.	1.1	4
90	Pulsatile ocular blood flow in asymmetric age-related macular degeneration. Eye, 2007, 21, 506-511.	1.1	11

#	ARTICLE	IF	CITATIONS
91	Intravitreal injection: balancing the risks. <i>Eye</i> , 2007, 21, 313-316.	1.1	7
92	Preliminary experience of ^{99m} Tcâ€Aprotinin scintigraphy in amyloidosis. <i>European Journal of Haematology</i> , 2007, 79, 494-500.	1.1	50
93	Two retinal vein occlusions in a patient with venous tortuosity at the optic disc. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2007, 245, 313-314.	1.0	5
94	Autofluorescence Characteristics of Early, Atrophic, and High-Risk Fellow Eyes in Age-Related Macular Degeneration. , 2006, 47, 5495.		140
95	Drusen classification in bilateral drusen and fellow eye of exudative age-related macular degeneration. <i>Eye</i> , 2006, 20, 199-202.	1.1	6
96	Screening for age-related macular degeneration using nonstereo digital fundus photographs. <i>Eye</i> , 2006, 20, 471-475.	1.1	26
97	Second eye of patients with unilateral neovascular age-related macular degeneration: Caucasians vs Chinese. <i>Eye</i> , 2006, 20, 923-926.	1.1	11
98	The complement system and age-related macular degeneration. <i>Eye</i> , 2006, 20, 867-872.	1.1	55
99	The impact of national diabetic retinopathy screening on ophthalmology: the need for urgent planning. <i>Eye</i> , 2006, 20, 1424-1425.	1.1	2
100	Evolving European guidance on the medical management of neovascular age related macular degeneration. <i>British Journal of Ophthalmology</i> , 2006, 90, 1188-1196.	2.1	62
101	Complement Factor H Variant Y402H Is a Major Risk Determinant for Geographic Atrophy and Choroidal Neovascularization in Smokers and Nonsmokers. , 2006, 47, 536.		172
102	Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. <i>Immunology</i> , 2005, 115, 422-430.	2.0	123
103	Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease?. <i>Clinical and Experimental Ophthalmology</i> , 2005, 33, 518-523.	1.3	49
104	An interinstitutional comparative study and validation of computer aided drusen quantification. <i>British Journal of Ophthalmology</i> , 2005, 89, 554-557.	2.1	13
105	Serum Elastin-Derived Peptides in Age-Related Macular Degeneration. , 2005, 46, 3046.		45
106	Choroidal translocation with a pedicle following excision of a type 1 choroidal neovascular membrane. <i>British Journal of Ophthalmology</i> , 2005, 89, 386-386.	2.1	14
107	Persistent Visual Loss After Retinochoroidal Infarction in Pregnancy-Induced Hypertension and Disseminated Intravascular Coagulation. <i>Journal of Neuro-Ophthalmology</i> , 2005, 25, 128-130.	0.4	13
108	Proportion of treatable subtypes of choroidal neovascular membranes in age-related macular degeneration. <i>International Congress Series</i> , 2005, 1282, 312-316.	0.2	0

#	ARTICLE	IF	CITATIONS
109	Decreased Thickness and Integrity of the Macular Elastic Layer of Bruch's Membrane Correspond to the Distribution of Lesions Associated with Age-Related Macular Degeneration. American Journal of Pathology, 2005, 166, 241-251.	1.9	185
110	In vivo demonstration of the anatomic differences between classic and occult choroidal neovascularization using optical coherence tomography. American Journal of Ophthalmology, 2005, 139, 344-346.	1.7	30
111	Modulation of Sub-RPE Deposits In Vitro: A Potential Model for Age-Related Macular Degeneration. Investigative Ophthalmology and Visual Science, 2004, 45, 1281-1288.	3.3	22
112	Radiotherapy for neovascular age-related macular degeneration. , 2004, , CD004004.		18
113	Fundus Autofluorescence in Patients with Leber Congenital Amaurosis. , 2004, 45, 2747.		55
114	TIMP-3 mRNA is not overexpressed in sorsby fundus dystrophy. American Journal of Ophthalmology, 2003, 136, 954-955.	1.7	18
115	Analysis of the Collagen VI Assemblies Associated with Sorsby's Fundus Dystrophy. Journal of Structural Biology, 2002, 137, 31-40.	1.3	30
116	Measurement of TIMP-3 Expression and Bruch's Membrane Thickness in Human Macula. Experimental Eye Research, 2001, 73, 851-858.	1.2	22
117	Comparison of optical coherence tomography and fluorescein angiography in assessing macular edema in retinal dystrophies: preliminary results. International Ophthalmology, 2001, 23, 321-325.	0.6	29
118	An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration. Progress in Retinal and Eye Research, 2001, 20, 705-732.	7.3	1,162
119	Optical Coherence Tomography and Electrophysiology in X-Linked Juvenile Retinoschisis Associated With a Novel Mutation in the XLR51 Gene. Retina, 2001, 21, 78-80.	1.0	50
120	Matrix metalloproteinase biology applied to vitreoretinal disorders. British Journal of Ophthalmology, 2000, 84, 654-666.	2.1	65
121	Management of inherited outer retinal dystrophies: present and future. British Journal of Ophthalmology, 1999, 83, 120-122.	2.1	28
122	An Immunohistochemical Study of an Autosomal Dominant Feline Rod/Cone Dysplasia (Rdy Cats). Experimental Eye Research, 1999, 68, 51-57.	1.2	34
123	Alternative therapies in exudative age related macular degeneration. British Journal of Ophthalmology, 1998, 82, 1441-1443.	2.1	22
124	Autofluorescence imaging. , 0, , 51-51.		0
125	Perspectives from clinical trials: is geographic atrophy one disease?. Eye, 0, , .	1.1	2